Filing Flows › Silence Therapeutics (SLN) › Q4 2024
Silence Therapeutics (SLN) Q4 2024 earnings results (fourth quarter 2024)
10-K filed Feb 27, 2025
Silence Therapeutics (SLN) reported revenue of $25.3M for the fourth quarter 2024 (Q4 2024) and up 17-fold from the quarter before. Operating margin was -17.2%, net earnings $12.3M (48.6% of revenue).
Silence Therapeutics, Q4 2024: revenue $25.3M, operating margin -17.2%, net earnings $12.3M, operating cash flow −$27.5M. The chart follows the revenue to costs, profit and cash.
| Q4 2024 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $25.3M | 17× | — |
| Operating profit | −$4.4M | — | — |
| Net earnings | $12.3M | — | — |
| Operating cash flow | −$27.5M | — | — |
What changed
Revenue was $25.3M in Q4 2024, up 1589% from the previous quarter.
Gross margin was 91.9%. Operating costs exceeded revenue by $4.4M, an operating margin of -17.2%. Net earnings were $12.3M. The effective tax rate was 2.6%. Non-operating items added $17.0M, 134% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$27.5M. Non-cash charges added back $76K of depreciation and $4.0M of share-based compensation. Working capital and other items used $43.8M. Capital expenditures of $62K exceeded it, leaving free cash flow of −$27.5M.
Questions
What was Silence Therapeutics' revenue in the fourth quarter 2024?
Silence Therapeutics (SLN) reported revenue of $25.3M for the fourth quarter 2024 (Q4 2024) and up 17-fold from the quarter before.
Was Silence Therapeutics profitable in the fourth quarter 2024?
Operating loss was $4.4M (-17.2% of revenue) and net earnings $12.3M.